Zealand Pharma (ZLDPF, Financial) has announced the rollout of its long-term incentive programs for 2025. These initiatives are aligned with its remuneration policy and guidelines for incentive pay, following approval at the annual general meeting that took place on March 20, 2024.
The company's new incentive plan includes the distribution of several restricted share units (RSUs) and performance share units (PSUs) across different tiers of its organizational structure. Specifically, 29,169 restricted share units have been allocated to the Board of Directors, while Corporate Management will receive 96,788 performance share units in addition to an equal number of RSUs. U.S. employees are set to obtain 18,502 RSUs, whereas their counterparts in Denmark will receive 128,519 RSUs.
These steps are part of Zealand Pharma’s ongoing strategy to align the interests of its leadership and workforce with the long-term success of the company, thereby driving sustained growth and shareholder value.
